Carbetocin

Carbetocin is a longer-acting relative of oxytocin, used medically to help prevent excessive bleeding after childbirth. Biohacker interest centers on anxiety and social effects; the clearest personal observations come from Prader–Willi caregivers discussing an experimental nasal spray, whose confirmatory trial did not show benefit over placebo.

An oxytocin analogue. It is a manufactured peptide that activates oxytocin receptors. In obstetric care, that helps the uterus contract after delivery and limits bleeding. It is not an organ-targeted bioregulator or a general-purpose bonding supplement. Duratocin — consumer and product information (Official context · Accessed 2026-09-30)

Different forms answer different questions. Pabal and Duratocin are medical injection names: into a vein (IV) or a muscle (IM). The Prader–Willi syndrome (PWS) program used an investigational nasal spray for food-related and behavioral difficulties. Neither context establishes subcutaneous self-injection for mood or libido. Pabal — Patient Information Leaflet (Official context · Accessed 2026-09-30) · Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Phase 3 COMPASS PWS (Official context · Accessed 2026-09-30)

Source context — Duratocin — consumer and product information: Medical obstetric labeling only; cannot verify gray-market quality, nasal mood effectiveness or long-term self-use safety. Interactions are cautioned by analogy with oxytocin, not established direct interaction trials.

Source context — Pabal — Patient Information Leaflet: Country-specific manufacturer leaflet; formulation identity only, not human mood evidence or a research-market route recommendation.

Source context — Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Phase 3 COMPASS PWS: Abstract, not full paper. PWS population, repeated trial nasal doses; no generalized mood indication or per-dose felt clock. Sponsor employees and investigator financial relationships are disclosed.

Less food-related distress. Some PWS caregivers described less food fixation, easier meal delays and fewer meltdowns when plans changed. These PWS observations do not establish calmer feelings in healthy adults. Caregiver Perspectives: Insights on the COMPASS-PWS Trial (Community guide · Accessed 2026-09-30)

Broader engagement. Families mentioned broader conversations and better focus or reasoning. These were retrospective caregiver impressions of everyday functioning, not controlled measurements or a demonstrated euphoric effect. Caregiver Perspectives: Insights on the COMPASS-PWS Trial (Community guide · Accessed 2026-09-30)

Medical benefit and mood hopes differ. Bleeding prevention is its documented obstetric purpose. The 175-person COMPASS PWS trial found no advantage over placebo on its efficacy measures; caregiver impressions do not reverse that result. Duratocin — consumer and product information (Official context · Accessed 2026-09-30) · Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Phase 3 COMPASS PWS (Official context · Accessed 2026-09-30)

Source context — Caregiver Perspectives: Insights on the COMPASS-PWS Trial: Foundation summary of retrospective caregiver feedback; not independent raw logs or all randomized participants. No reliable per-dose onset, duration or nasal half-life. Trial-related institutional involvement matters; the 2026 abstract discloses foundation funding from Acadia.

Source context — Duratocin — consumer and product information: Medical obstetric labeling only; cannot verify gray-market quality, nasal mood effectiveness or long-term self-use safety. Interactions are cautioned by analogy with oxytocin, not established direct interaction trials.

Source context — Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Phase 3 COMPASS PWS: Abstract, not full paper. PWS population, repeated trial nasal doses; no generalized mood indication or per-dose felt clock. Sponsor employees and investigator financial relationships are disclosed.

No dependable biohacker amount. These discussions do not establish a Carbetocin self-use dose. Hospital posts and a clinician's social thread concern obstetric practice or studies; they are not mood protocols. Medical and trial amounts appear separately below. Oxytocin — PheroTruth page 9 (Community discussion · Accessed 2026-09-30) · Obs questions (Community discussion · Accessed 2026-09-30) · Dr. Ron George — obstetric anesthesia tweetorial (Thread Reader mirror) (Secondhand community claim · Accessed 2026-09-30)

One obstetric dose versus repeated nasal research. Australian product information describes 100 micrograms IV after cesarean delivery, or IV/IM after vaginal delivery, once. COMPASS studied 3.2 mg intranasally per administration, three times daily for 12 weeks (9.6 mg daily in total). Different routes and purposes make these unsuitable as a self-use progression. Duratocin — Australian Product Information (2018 AusPAR attachment) (Official context · Accessed 2026-09-30) · Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Phase 3 COMPASS PWS (Official context · Accessed 2026-09-30)

Source context — Oxytocin — PheroTruth page 9: Historical enthusiast-forum archive; anonymous and unverified. No completed Carbetocin report, quantity or Carbetocin timing measurement. Formulation mixing discussion is omitted rather than supplied as instructions.

Source context — Obs questions: Self-described clinician practice is unverified and institution-specific. Oxytocin amounts in the thread are not Carbetocin amounts; no biohacker protocol or firsthand subjective Carbetocin effect is established.

Source context — Dr. Ron George — obstetric anesthesia tweetorial (Thread Reader mirror): Inspected mirror, not direct X. Clinician's repetition of formal obstetric research, not a personal biohacker dosing account. Unitless numbers cannot be promoted to a community dose range.

Source context — Duratocin — Australian Product Information (2018 AusPAR attachment): Historical country-specific label. Blood study involved healthy nonpregnant women and 400/800-microgram injections, unlike the obstetric 100-microgram dose or nasal PWS formulation. Uterine response is not mood timing.

Source context — Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Phase 3 COMPASS PWS: Abstract, not full paper. PWS population, repeated trial nasal doses; no generalized mood indication or per-dose felt clock. Sponsor employees and investigator financial relationships are disclosed.

No reliable minutes-to-mood clock. Caregiver feedback describes behavior during treatment, without a dependable first-dose onset. Families themselves questioned whether changes were treatment effects or ordinary fluctuations. Caregiver Perspectives: Insights on the COMPASS-PWS Trial (Community guide · Accessed 2026-09-30)

Stopping observations are not a dose timer. Some parents noticed differences most clearly after treatment stopped. That does not establish how many hours a nasal dose feels active or how long changes persist. Caregiver Perspectives: Insights on the COMPASS-PWS Trial (Community guide · Accessed 2026-09-30)

Blood measurements are not felt duration. An injection-study program involving 25 healthy nonpregnant women reported 41 ± 11.9 minutes for the later blood-level decline by half after 400 micrograms IV; the early distribution half-life was 5.5 ± 1.6 minutes as the drug moved through the body. IM blood levels peaked at 20–30 minutes, with about 80% reaching circulation. None measures nasal mood timing. Duratocin — Australian Product Information (2018 AusPAR attachment) (Official context · Accessed 2026-09-30)

No community nasal-spray measurement. The discussions do not provide a measured Carbetocin half-life for nasal mood use. Oxytocin's short half-life is part of the interest in alternatives, but it cannot supply Carbetocin's number or predict how it feels. Synthetic oxytocin may prevent anxiety caused by social stress, according to a study in an animal model (Community discussion · Accessed 2026-09-30) · Oxytocin — PheroTruth page 9 (Community discussion · Accessed 2026-09-30)

Source context — Caregiver Perspectives: Insights on the COMPASS-PWS Trial: Foundation summary of retrospective caregiver feedback; not independent raw logs or all randomized participants. No reliable per-dose onset, duration or nasal half-life. Trial-related institutional involvement matters; the 2026 abstract discloses foundation funding from Acadia.

Source context — Duratocin — Australian Product Information (2018 AusPAR attachment): Historical country-specific label. Blood study involved healthy nonpregnant women and 400/800-microgram injections, unlike the obstetric 100-microgram dose or nasal PWS formulation. Uterine response is not mood timing.

Source context — Synthetic oxytocin may prevent anxiety caused by social stress, according to a study in an animal model: Secondhand animal-study discussion and opinions, not human Carbetocin use. Some replies concern oxytocin instead. No source establishes a human social-anxiety response or Carbetocin nasal half-life.

Source context — Oxytocin — PheroTruth page 9: Historical enthusiast-forum archive; anonymous and unverified. No completed Carbetocin report, quantity or Carbetocin timing measurement. Formulation mixing discussion is omitted rather than supplied as instructions.

Obstetric use: The reviewed product information describes one clinician-administered postpartum dose; seasonal or repeated courses do not apply. [trial]

PWS research duration: COMPASS PWS used repeated intranasal administration for 12 weeks. This was a clinical-trial period, not a validated on/off cycle for general use. [trial]

Longer trials were a caregiver proposal. Families suggested extending the 12-week trial to at least 16 weeks. This was a study-design opinion, not a demonstrated cycle, break interval or restart rule for self-use. Caregiver Perspectives: Insights on the COMPASS-PWS Trial (Community guide · Accessed 2026-09-30)

Source context — Caregiver Perspectives: Insights on the COMPASS-PWS Trial: Foundation summary of retrospective caregiver feedback; not independent raw logs or all randomized participants. No reliable per-dose onset, duration or nasal half-life. Trial-related institutional involvement matters; the 2026 abstract discloses foundation funding from Acadia.

Product uncertainty and stack confusion. Research-market impurities and allergy remain concerns, and long-term self-use safety is unclear. Redness, itching, lumps or bruising are generic injection cautions, not proof that subcutaneous Carbetocin is an established route. Multi-compound experiments make both benefits and side effects hard to attribute; no verified mood stack emerges here. New neurological symptoms or uncontrolled blood pressure or glucose also need real care, not forum advice.

Obstetric co-treatment context: Trials and product information compare carbetocin with oxytocin or describe additional uterotonics when clinically needed; this is not a multi-bioregulator stack. [trial]

Attribution: A personal n=1 claim or multi-compound anecdote would not establish a carbetocin mood combination. The inspected co-medication context concerns monitored obstetric care. [community] [trial]

Pregnancy is a major boundary. The injection must not be used before the baby is delivered or to induce labor. Its uterine effects cannot be promptly stopped like an oxytocin infusion. Cardiovascular disease and allergy to either peptide are important label contraindications. Duratocin — consumer and product information (Official context · Accessed 2026-09-30)

Feeling unwell is not proof of a mood effect. Medical reports include nausea, abdominal pain, itching, flushing, warmth, vomiting, low blood pressure, headache and tremor; childbirth and anesthesia complicate attribution. Severe allergy, chest pain or fainting require urgent medical assessment. Possible oxytocin-like interactions remain relevant despite limited direct interaction data. Duratocin — consumer and product information (Official context · Accessed 2026-09-30)

An oxytocin experience can be mistaken for Carbetocin. On PheroTruth, siddie described six hours of emotional effects from oxytocin; Ekscentra then mentioned possibly testing Carbetocin. The six-hour account belongs to oxytocin. It is not a Carbetocin duration report, and the thread supplies no completed Carbetocin experiment. Oxytocin — PheroTruth page 9 (Community discussion · Accessed 2026-09-30)

Product uncertainty and stack confusion. Research-market impurities and allergy remain concerns, and long-term self-use safety is unclear. Redness, itching, lumps or bruising are generic injection cautions, not proof that subcutaneous Carbetocin is an established route. Multi-compound experiments make both benefits and side effects hard to attribute; no verified mood stack emerges here. New neurological symptoms or uncontrolled blood pressure or glucose also need real care, not forum advice.

Source context — Duratocin — consumer and product information: Medical obstetric labeling only; cannot verify gray-market quality, nasal mood effectiveness or long-term self-use safety. Interactions are cautioned by analogy with oxytocin, not established direct interaction trials.

Source context — Oxytocin — PheroTruth page 9: Historical enthusiast-forum archive; anonymous and unverified. No completed Carbetocin report, quantity or Carbetocin timing measurement. Formulation mixing discussion is omitted rather than supplied as instructions.